<DOC>
	<DOCNO>NCT00661401</DOCNO>
	<brief_summary>Objective : Measure serum IgG antibody Streptococcus pneumoniae serotypes 1 , 3 , 5 , 6B , 9V e 14 , Haemophilus influenzae type b tetanus toxoid patient primary antibody deficiency treat subcutaneous immunoglobulin infusion .</brief_summary>
	<brief_title>Specific IgG Antibody Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin</brief_title>
	<detailed_description>Therapy polyvalent immunoglobulin ( Ig ) establish standard therapy antibody deficiencies several decade . Although subcutaneous infusion originally propose alternative intramuscular injection , recently , method proven safe convenient method provide immunoglobulin level adult child . Subcutaneous administration immunoglobulins clinical advantage intravenous immunoglobulin infusion ( IVIG ) , include benign side effect profile , good sustain level IgG blood reduce cost . An additional benefit improvement quality life , part secondary feasibility patient administer home . The common infection primary antibody deficiency patient involve encapsulated bacteria , mainly Streptococcus pneumoniae Haemophilus influenzae type b . The aim study verify patient antibody deficiency receive subcutaneous immunoglobulin ( SCIG ) infusion keep protective antibody level Streptococcus pneumoniae , Haemophilus influenzae type b ( Hib ) tetanus toxoid .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>diagnosis primary immunodeficiency disease hypoor agammaglobulinemia diagnosis perform accord WHO definition already treat Intravenous immunoglobulin subcutaneous immunoglobulin least 6 month prior enrollment study document IgG trough level ( least two value ) , type use IgG preparation , dosage dosage interval period 6 month prior enrollment study history hypersensitivity study medication drug similar chemical structure hypersensitivity IgA subject currently require &lt; 400 &gt; 600 mg/kg/b.w . immunoglobulin per month subject whose dosage interval IV Ig &lt; 3 week know pregnancy positive pregnancy test nursing mother childbearing potential , acceptable birth control practice history chronic persist renal insufficiency ( serum creatinine upper limit normal ) history chronic persisting hepatic insufficiency ( ALT &gt; 2 time upper limit normal ) risk develop acute renal failure ( Diabetes mellitus , volume depletion , sepsis , paraproteinemia ) symptomatic heart disease require treatment ( NYHA class II ) history seizure disorder history risk occlusive vascular disease indication active hepatitis A , B , C screening ( HAVPCR , HBVPCR , HCVPCR positive ) detection HIV1 PCR positive likelihood require treatment study period drug permit study protocol progressive fatal disease/life expectancy le 12 month history drug alcohol abuse pathological mental condition render subject unable understand , scope possible consequence study and/or evidence uncooperative attitude treatment nephrotoxic drug last 3 week treatment investigational drug last 3 month study entry likelihood treatment another investigational grug study period evidence uncooperative attitude vaccination hepatitis B within 3 month enrollment study former participation trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>gammaglobulin</keyword>
	<keyword>subcutaneous infusion</keyword>
	<keyword>specific antibody</keyword>
	<keyword>primary antibody deficiency</keyword>
</DOC>